Utilizing immune signatures for breast cancer subtyping in treatment approaches
Breast cancer, a prevalent form of cancer in women, presents various categories that pose challenges in defining specific treatment approaches. Immunohistochemistry, a combination of immunology and histology, has made significant advancements in identifying specific surface receptors on cancer cell...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Trường Đại học Vinh
2023-06-01
|
| Series: | Tạp chí Khoa học |
| Subjects: | |
| Online Access: | https://vujs.vn//api/view.aspx?cid=1e472e15-098e-4215-8e08-492a251efc78 |
| _version_ | 1797789265616175104 |
|---|---|
| author | Nguyen Thi Giang An |
| author_facet | Nguyen Thi Giang An |
| author_sort | Nguyen Thi Giang An |
| collection | DOAJ |
| description | Breast cancer, a prevalent form of cancer in women, presents various categories that pose challenges in defining specific treatment approaches. Immunohistochemistry, a combination of immunology and histology, has made significant advancements in identifying specific surface receptors on
cancer cells. This information serves as the basis for guiding appropriate treatment regimens and predicting prognosis for patients. A survey conducted on 75 tissue samples revealed the diversity of breast carcinoma types, with the infiltrative tubular form being the most common, accounting for 73.3%
of cases. By utilizing immunoassay markers on these tissues, the expression rates of ER (estrogen receptor), PR (progesterone receptor), and Her2/neu were determined to be 29.2%, 52%, and 22.7%, respectively. Classification of breast
cancer based on these markers showed that the ER/PR+HER2- group accounted for 24% of cases. The ER-/PR+HER2- group accounted for 18.7%, while the
ER+/PR+HER2+, ER-/PR+HER2+, and ER-PR+Her2+ groups each represented 12% of cases. The ER-/PRHER2+HER2+ group accounted for 8%, and a subgroup
where all three markers were negative accounted for 22.7% of cases. Estrogen and progesterone expression showed a moderately positive correlation (0 < r = 0.445 < 0.5; p <0.05). However, the expression of Her2/neu in ER-negative
tumors did not show statistical significance (p > 0.05) and exhibited a reverse correlation with r = -0.016 |
| first_indexed | 2024-03-13T01:48:15Z |
| format | Article |
| id | doaj.art-25fa21d9560e4dc891518f5efb82cf52 |
| institution | Directory Open Access Journal |
| issn | 1859-2228 |
| language | English |
| last_indexed | 2024-03-13T01:48:15Z |
| publishDate | 2023-06-01 |
| publisher | Trường Đại học Vinh |
| record_format | Article |
| series | Tạp chí Khoa học |
| spelling | doaj.art-25fa21d9560e4dc891518f5efb82cf522023-07-03T02:29:00ZengTrường Đại học VinhTạp chí Khoa học1859-22282023-06-01522A687910.56824/vujs.2022a071Utilizing immune signatures for breast cancer subtyping in treatment approachesNguyen Thi Giang An0School of Education, Vinh University, VietnamBreast cancer, a prevalent form of cancer in women, presents various categories that pose challenges in defining specific treatment approaches. Immunohistochemistry, a combination of immunology and histology, has made significant advancements in identifying specific surface receptors on cancer cells. This information serves as the basis for guiding appropriate treatment regimens and predicting prognosis for patients. A survey conducted on 75 tissue samples revealed the diversity of breast carcinoma types, with the infiltrative tubular form being the most common, accounting for 73.3% of cases. By utilizing immunoassay markers on these tissues, the expression rates of ER (estrogen receptor), PR (progesterone receptor), and Her2/neu were determined to be 29.2%, 52%, and 22.7%, respectively. Classification of breast cancer based on these markers showed that the ER/PR+HER2- group accounted for 24% of cases. The ER-/PR+HER2- group accounted for 18.7%, while the ER+/PR+HER2+, ER-/PR+HER2+, and ER-PR+Her2+ groups each represented 12% of cases. The ER-/PRHER2+HER2+ group accounted for 8%, and a subgroup where all three markers were negative accounted for 22.7% of cases. Estrogen and progesterone expression showed a moderately positive correlation (0 < r = 0.445 < 0.5; p <0.05). However, the expression of Her2/neu in ER-negative tumors did not show statistical significance (p > 0.05) and exhibited a reverse correlation with r = -0.016https://vujs.vn//api/view.aspx?cid=1e472e15-098e-4215-8e08-492a251efc78breast cancerimmunohistochemistryher2/neuer/pr |
| spellingShingle | Nguyen Thi Giang An Utilizing immune signatures for breast cancer subtyping in treatment approaches Tạp chí Khoa học breast cancer immunohistochemistry her2/neu er/pr |
| title | Utilizing immune signatures for breast cancer subtyping in treatment approaches |
| title_full | Utilizing immune signatures for breast cancer subtyping in treatment approaches |
| title_fullStr | Utilizing immune signatures for breast cancer subtyping in treatment approaches |
| title_full_unstemmed | Utilizing immune signatures for breast cancer subtyping in treatment approaches |
| title_short | Utilizing immune signatures for breast cancer subtyping in treatment approaches |
| title_sort | utilizing immune signatures for breast cancer subtyping in treatment approaches |
| topic | breast cancer immunohistochemistry her2/neu er/pr |
| url | https://vujs.vn//api/view.aspx?cid=1e472e15-098e-4215-8e08-492a251efc78 |
| work_keys_str_mv | AT nguyenthigiangan utilizingimmunesignaturesforbreastcancersubtypingintreatmentapproaches |